| Friday, November 2 |
| 7:50 am - 8:00 am |
President's Welcome
Jon M. Wigginton, MD - Merck & Co., Inc. |
| 8:00 am - 8:45 am |
Richard V. Smalley Memorial Lectureship
Interferons (IFNs) for Cancer: Defining Biological Response
Modification and
Full Therapeutic Potential
 Ernest C. Borden, MD - Cleveland Clinic Foundation |
| 8:45 am - 11:30 am |
Plenary Session: Cellular Therapies
Co-Chairs:
Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
James C. Yang, MD - National Cancer Institute
|
| 8:45 am - 9:15 am |
Adoptive Cellular Therapy: Sustained Regression of Large Tumor Burdens with In Vitro Expanded T-Cells
James C. Yang, MD - National Cancer Institute
|
| 9:15 am - 9:45 am |
Targeting Tumors with Genetically Enhanced T Lymphocytes
Michel Sadelain, MD, PhD - Memorial Sloan-Kettering Cancer Center
|
| 9:45 am - 10:15 am |
Engineering Cytolytic Effector Cells for Glioma Immunotherapy
Using Gene Insertion and Zinc Finger Nuclease Genomic Editing
Michael C.V. Jensen, MD - City of Hope / Beckman Research Institute
|
| 10:45 am - 11:00 am |
A Comprehensive Platform for T Cell Expansion Based on
Biodegradable Artificial Antigen-Presenting Microparticulates
Tarek Fahmy, PhD - Yale University
|
| 11:00 am - 11:15 am |
Tumor-Specific CD4 T Cells are Required for Long-Term Anti-Tumor
Immunity in Reconstituted Lymphopenic Animals
Kevin Friedman, PhD - Earle A. Chiles Research Institute
|
| 11:15 am - 11:30 am |
T-Cell Therapy for the Control of EBV-Related Nasopharyngeal Carcinoma
Paulo Pedrazzoli, MD - Ospedale Niguarda Ca’ Granda
|
| 1:30 pm - 3:30 pm |
Plenary Session: Characterizing the Host Response to Cancer
Co-Chairs:
George Coukos, MD, PhD - University of Pennsylvania Medical Center
Thomas F. Gajewski, MD, PhD - University of Chicago
|
| 1:30 pm - 2:00 pm |
Stat3 Mediates a Crosstalk Between Tumor Cells and Immune Cells
in the Tumor Microenvironment
Hua Yu, PhD - City of Hope National Medical Center
|
| 2:00 pm - 2:15 pm |
Antibody Immunity to a Panel of Oncogenic Proteins May Predict
Presence of Colon Cancer and Stage of Disease
Vivian Goodell, MPH - University of Washington
|
| 2:15 pm - 2:30 pm |
A Possible Role for Regulatory T-Cells in Survival Differences Between Helicobacter Pylori Posititve and Negative Gastric
Cancer Patients After Curative Tumor Resection
Hauke Winter, MD - Klinikum Grosshadern, Ludwig-Maximilians University of Munich
|
| 2:30 pm - 2:45 pm |
Immunophenotypic Analysis of Melanoma Metastases: A New Approach for Prognostication in Stage IV Melanoma
Alicia M. Terando, MD - John Wayne Cancer Institute
|
| 2:45 pm - 3:00 pm |
A Cell-Based Vaccine for Neuroblastoma Induces VLA-2 (CD49b) on
CD8+ T Effector/Memory Cells Via CD137
Rimas J. Orentas, PhD - Medical College of Wisconsin
|
| 3:00 pm - 3:30 pm |
Endothelin (B) Receptor Mediates the Endothelial Barrier to T-Cell Homing to Tumors, and Its Neutralization Enables Tumor
Immune Therapy
George Coukos, MD, PhD - University of Pennsylvania Medical Center
|
| 3:45 pm - 5:15 pm |
Concurrent Session I: Cytokines
Co-Chairs:
Michael T. Lotze, MD - University of Pittsburgh
Crystal Mackall, MD - National Cancer Institute
|
| 3:45 pm - 4:15 pm |
Interleukin 1 Family Members Regulate Tumor Immunity in Response
to Damage Associated Molecular Pattern Molecules (DAMPs)
Michael T. Lotze, MD - University of Pittsburgh Cancer Institute
|
| 4:15 pm - 4:30 pm |
IL-24 and Its Role in Wound Healing
Nancy J. Poindexter, PhD - MD Anderson Cancer Center
|
| 4:30 pm - 4:45 pm |
Intra-Tumoral IL-12 Promotes CD8 + T-Effector/Memory Cell-
Mediated IFN-Gamma and FASL-Dependent Elimination of CD4+ CD25+
FOX3+ T-Suppressor Cells from Tumors
Mehmet O. Kilinc, PhD - University at Buffalo / SUNY
|
| 4:45 pm - 5:15 pm |
Interleukin-7 Therapy in Humans: Proof-of-Principle
Crystal Mackall, MD - National Cancer Institute, Pediatric Oncology
|
| 3:45 pm - 5:15 pm |
Concurrent Session II: Angiogenesis and Vascular Therapies
Co-Chairs:
Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
Renata Pasqualini, PhD - MD Anderson Cancer Center
|
| 3:45 pm - 3:50 pm |
Introduction
Renata Pasqualini, PhD - MD Anderson Cancer Center
|
| 3:50 pm - 4:25 pm |
Ligand-Directed Targeting and Molecular Genetic Imaging in
Diseases with an Angiogenesis Component
Wadih Arap, MD, PhD - MD Anderson Cancer Center
|
| 4:25 pm - 5:00 pm |
Tie2-Expressing Monocytes: a Novel Lineage of Proangiogenic Cells
Luigi Naldini, PhD - San Raffaele Telethon Institute for Gene Therapy
|
| 5:00 pm - 5:15 pm |
Impaired Angiogenesis in Aminopeptidase N-Null Mice
Roberto Rangel, PhD - MD Anderson Cancer Center
|
| Saturday, November 3 |
| 8:00 am - 8:45 am |
Saturday Keynote Address
Adoptive T Cell Therapy: Grand Challenges and Opportunities
Carl H. June, MD - University of Pennsylvania |
| 8:45 am - 11:30 am |
Plenary Session: Immuoregulation and Mediated Tolerance
Co-Chairs:
Vincenzo Bronte, MD - Istituto Oncologico Veneto
F. Stephen Hodi, MD - Dana-Farber Cancer Institute
|
| 8:45 am - 9:00 am |
Elevated Foxp3+CD4+CD25+ Regulatory T Cells in Tumor-Bearing
Mice Suppress T-Cell Priming, Effector-Cell Function and Anti-Tumor Immunity
Zuqiang Liu, PhD - University of Pittsburgh School of Medicine |
| 9:00 am - 9:30 am |
Manipulating Immune Tolerance Unmasks the Latent Immune-Modulating Potential of Cancer Therapeutics
Leisha A. Emens, MD, PhD - Johns Hopkins University |
| 9:30 am - 9:45 am |
Different Flavors of Regulatory T-Cell (Treg) Subsets in
Patients with Cancer and Their Role in Tumor Escape
Christoph Bergmann, MD, PhD - University of Duisburg-Essen |
| 9:45 am - 10:00 am |
Ex Vivo Depletion of CD81+ Tumor-Induced Regulatory T Cells Restores Priming of Tumor-Specific Effector T Cells Generated in
Reconstituted, Lymphopenic Hosts
Christian Poehlein, MD - Earle A. Chiles Research Institute |
| 10:00 am - 10:15 am |
Foxp3 is Expressed by Tumor Cells, Virally Transformed B Cells, and Germ Cells
Weisan Chen, PhD - Ludwig Institute for Cancer Research |
| 10:45 am - 11:00 am |
TGF-Beta Signaling Plays a Crucial Role for De Novo Induction of
Adaptive Regulatory T Cells but Is Not Required for the
Immunosuppressive Effect Mediated by Tumor-Induced Regulatory T Cells
Ulf Petrausch, MD - Earle A. Chiles Research Institute |
| 11:00 am - 11:30 am |
Myeloid-Derived Suppressor Cells in Cancer
Vincenzo Bronte, MD - Istituto Oncologico Veneto |
| 1:30 pm - 3:00 pm |
Concurrent Session I: Tumor Recognition / Immune Evasion
Co-Chairs:
Paul F. Robbins, PhD - National Cancer Institute
Thomas Spies, PhD - Fred Hutchinson Cancer Research Center
|
| 1:30 pm - 2:00 pm |
Adoptive Immunotherapy of Malignancies with Gene Modified, EBV-Specific, Cytotoxic T-Cell Lines
Malcolm K. Brenner, MD, PhD - Baylor College of Medicine |
| 2:00 pm - 2:30 pm |
Therapeutically Accessible Molecules That Regulate the Regulators
Drew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine |
| 2:30 pm - 2:45 pm |
Tumor-Derived Macrophage Migration Inhibitory Factor (MIF)
Inhibits Immune Reactivity to Neuroblastoma In Vivo
Bryon D. Johnson, PhD - Medical College of Wisconsin |
| 2:45 pm - 3:00 pm |
5-aza-2’- Deoxycytidine Treatment Increases Expression of Tumor
Associated Antigens in Human Melanoma
Timothy Haggerty, PhD - CytoCure LLC |
| 1:30 pm - 3:00 pm |
Concurrent Session II: New Agents
Co-Chairs:
Elizabeth A. Repasky, PhD - Rosewell Park Cancer Institute
Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
|
| 1:30 pm - 1:45 pm |
PTTG-1: An Immunological Target for Multiple Myeloma
Maurizio Chiriva, PhD - Texas Tech University Health Sciences Center |
| 1:45 pm - 2:00 pm |
A Phase II Study of Tremelimumab (CP-675,206), an Anti-CTLA4
Monoclonal Antibody, in Patients with Refractory Metastatic Colorectoal Cancer
Ki Y. Chung, MD - Memorial Sloan-Kettering Cancer Center |
| 2:00 pm - 2:15 pm |
Immune-Related Adverse Events in Patients with Melanoma Treated with Tremelimumab (CP-675,206)
Dimitri Pavlov, PhD - Pfizer, Inc. |
| 2:15 pm - 2:30 pm |
EGFRVIII Vaccine (CDX-110) Alone and with Simultaneous
Temozolomide in Patients with Newly Diagnosed, Resected, EGFRVIII Positive GBM
John Sampson, MD, PhD - Duke University Medical Center |
| 2:30 pm - 3:00 pm |
Novel Agents in Renal Cell Carcinoma: Challenges and
Opportunities in Capitalizing on Active Therapy
Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center |
| 3:20 pm - 4:45 pm |
iSBTc Presidential Session
Chair: Jon M. Wigginton, MD - Merck & Co., Inc.
|
| 3:20 pm - 3:25 pm |
Introduction
Jon M. Wigginton, MD - Merck & Co., Inc. |
| 3:25 pm - 3:45 pm |
Apoptosis of Circulating Tumor-Antigen Specific TH1 CD4+ T Cells from Melanoma Patients
Amy K. Wesa, PhD - University of Pittsburgh School of Medicine |
| 3:45 pm - 4:05 pm |
Priming and Selection of Allorestricted, Peptide-Specific T Cells for Adoptive Therapy of Tumors
Susanne Wilde - Institute of Molecular Immunology |
| 4:05 pm - 4:25 pm |
Retrospective Analysis of Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma Who had Received Prior
Antiangiogenic Therapy
Talya Schwarzberg, MD - Beth Israel Deaconess Medical Center |
| 4:25 pm - 4:45 pm |
CD4+CD25highFoxp3+ T Regulatory Cells Kill Autologous CD8(+) and
CD4(+) T Cells Using GranzymeB and Fas/FasL-Mediated Pathways
Laura Strauss, PhD - San Raffaele Telethon Institute for Gene Therapy |
| Sunday, November 4 |
| 8:00 am - 8:30 am |
Update: 2006 Mini-Symposium Update
Chair:
George Coukos, MD, PhD - University of Pennsylvania Medical Center
Speaker:
Michael B. Atkins, MD - Beth Israel Deaconess Medical Center |
| 8:30 am - 8:45 am |
Update: National Cancer Institute Immunotherapy Agent Workshop
Martin A. Cheever, MD - Fred Hutchinson Cancer Research Center |
| 8:45 am - 11:00 am |
Plenary Session: Vaccines / Dendritic Cells
Co-Chair:
Mary L. Disis, MD - University of Washington
Lothar H. Finke, MD - ARGOS Therapeutics |
| 8:45 am - 9:15 am |
The Development of Provenge® (Sipuleucel-T) an Active Cellular
Immunotherapy for Prostate Cancer
David L. Urdal, PhD - Dendreon Corporation |
| 9:15 am - 9:30 am |
Long-Term Survival in Patients with Metastatic Melanoma Vaccinated
with Melanoma-Antigen Loaded Dendritic Cells
Joseph W. Fay, MD - Baylor University Medical Center |
| 9:30 am - 9:45 am |
Phase II Trial of a 10-Epitope CTL Vaccine, IDM-2101, in
Metastatic NSCLC Patients: Induction of Immune Responses and Clinical Efficacy
Minal Barve, MD - Mary Crowley Cancer Research Centers |
| 9:45 am - 10:00 am |
Different DC Populations Interact with Memory & Effector T Cells, or with Treg Cells
Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute |
| 10:00 am - 10:15 am |
Features of Lympoid Neogenesis After Dermal Injection of Incomplete
Freund’s Adjuvant with or without Peptides
Craig L. Slingluff, Jr., MD - University of Virginia |
| 10:15 am - 10:30 am |
IMA901, a Novel Multi-Peptide Vaccine for the Treatment of Renal
Cell Carcinoma - Pre-Clinical and Clinical Studies and Implications for Combination with Other Agents
Harpreet Singh, PhD - Immatics Biotechnologies GmbH |
| 10:30 am - 11:00 am |
Insulin like Growth Factor Receptor Family Members: Essential Tumor Antigens in Breast Cancer
Mary L. Disis, MD - University of Washington |
| 11:00 am - 11:15 am |
Refreshment Break |
| 11:15 am - 12:45 pm |
Hot Topic Sessions: Vaccines / Dendritic Cells
Moderators:
Bernard A. Fox, PhD - Earle A. Chiles Research Institute
Jon M. Wigginton, MD - Merck & Co., Inc.
Participants:
Brent A. Blumenstein, PhD - TriArc Consulting
Lee S. Simon, MD - Beth Israel Deaconess Medical Center
Charles Drake, MD, PhD - Johns Hopkins University
David L. Urdal, PhD - Dendreon Corporation
James W. Young, MD - Memorial Sloan-Kettering Cancer Center |
| 12:45 pm |
Meeting Adjourns |
